Glabellar Lines Clinical Trial
Official title:
Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines: Multi-center, Single Arm, Open, Extension Study
Verified date | June 2017 |
Source | Daewoong Pharmaceutical Co. LTD. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to explore the Efficacy and Safety of DWP450 for treating Crows Feet Lines(CFL) in combination with glabellar line(GL) as extension study of phase 3 study for CFL.
Status | Not yet recruiting |
Enrollment | 102 |
Est. completion date | December 2017 |
Est. primary completion date | October 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Male or female of at least 18 to 75 years old - moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator - moderate-to-severe GL at maximum frawn on the FWS as rated by the investigator - Subject who has completed phase 3 study for CFL. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Daewoong Pharmaceutical Co. LTD. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subject Assessment of Satisfaction of Appearance | Subject Assessment of Satisfaction of Appearance | At 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04096326 -
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
|
Phase 2 | |
Completed |
NCT02961673 -
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
|
Phase 1/Phase 2 | |
Completed |
NCT01271452 -
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
|
Phase 4 | |
Completed |
NCT05013424 -
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
|
Phase 2 | |
Completed |
NCT01189760 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
Completed |
NCT05100199 -
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
|
Phase 2 | |
Completed |
NCT03721016 -
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
|
Phase 3 | |
Completed |
NCT04157686 -
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
|
Phase 3 | |
Completed |
NCT02353897 -
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
|
||
Completed |
NCT03732833 -
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
|
Phase 3 | |
Completed |
NCT06212960 -
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
|
Phase 1 | |
Completed |
NCT05089357 -
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
|
||
Completed |
NCT00408785 -
A Study Of BOTOX For The Treatment Of Glabellar Lines
|
Phase 3 | |
Completed |
NCT05380154 -
Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.
|
Phase 3 | |
Completed |
NCT01224015 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
Completed |
NCT05248880 -
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
|
Phase 3 | |
Completed |
NCT03216408 -
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines
|
Phase 3 | |
Recruiting |
NCT06308198 -
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
|
Phase 3 | |
Completed |
NCT05298449 -
Phase 2 of HU-045 in Glabellar Lines
|
Phase 2 | |
Not yet recruiting |
NCT06246552 -
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
|
Phase 2 |